Kirsten Carmel focuses on biopharma reimbursement and health policy and has worked with biopharmaceutical and related companies for over 20 years on business strategy, business development and public affairs in the US, EU, China and Emerging Markets. Kirsten is an economist who works with healthcare clients on issues including Medicare reimbursement, payer contract negotiations, designing innovative reimbursement contracts. Kirsten works with biopharma, trade associations and health IT companies on pricing, market size assessment, reimbursement, patient assistance, public affairs, industrial organization, and strategic matters. She has worked to develop policy platforms for CEO's and their organizations, including public positions on drug pricing, insurance coverage and regulatory reform. She has helped to establish pricing and estimate market size for medicines including in rare disease and oncology considering value and affordability. Kirsten has guided the development of patient financial assistance programs for biopharma. She often uses financial models and data analytics to demonstrate how different stakeholders in the healthcare delivery chain are affected by policy and business practice to guide corporate policy and business practice recommendations and to estimate the impact of policy change for corporate financial disclosure. Kirsten is a Health Innovator Fellow with The Aspen Institute, and a Visiting Scholar with The American Enterprise Institute. She is the Executive Secretary of the non-profit Preparedness and Treatment Equity Coalition, dedicated to achieving equity in health delivery by funding research into novel uses of data and outcomes metrics. She has an M.S. in Economics from the University of Texas, Austin and is published for work in health policy and health economics.